Comparing AnaptysBio (ANAB) & Its Competitors

AnaptysBio (NASDAQ: ANAB) is one of 481 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare AnaptysBio to similar companies based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.

Profitability

How to Become a New Pot Stock Millionaire

This table compares AnaptysBio and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AnaptysBio N/A -19.16% -16.88%
AnaptysBio Competitors -3,117.69% -153.03% -26.89%

Insider & Institutional Ownership

99.3% of AnaptysBio shares are held by institutional investors. Comparatively, 47.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.3% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares AnaptysBio and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AnaptysBio $10.00 million -$30.07 million -56.26
AnaptysBio Competitors $2.04 billion $133.73 million -3.24

AnaptysBio’s rivals have higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for AnaptysBio and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AnaptysBio 0 1 7 0 2.88
AnaptysBio Competitors 2762 8403 21176 565 2.59

AnaptysBio currently has a consensus price target of $138.63, indicating a potential upside of 62.12%. As a group, “Pharmaceutical preparations” companies have a potential upside of 49.93%. Given AnaptysBio’s stronger consensus rating and higher probable upside, research analysts clearly believe AnaptysBio is more favorable than its rivals.

Volatility & Risk

AnaptysBio has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500. Comparatively, AnaptysBio’s rivals have a beta of 1.08, suggesting that their average share price is 8% more volatile than the S&P 500.

Summary

AnaptysBio beats its rivals on 8 of the 13 factors compared.

About AnaptysBio

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply